Frontotemporal Dementia

Scientists still don't fully understand why brain cells die in genetic frontotemporal dementia. Using single-cell genome sequencing of 469 individual neurons, including from people with C9ORF72-linked FTD, this study found that affected neurons accumulate more DNA damage than healthy ones, following a distinctive pattern that points to oxidative stress. The damage was especially common in FTD neurons. Identifying a shared, gene-linked mechanism of neuronal injury across FTD and related diseases opens potential new directions for protecting brain cells.

Most genetic frontotemporal dementia is caused by changes in three well-known genes (C9orf72, GRN, or MAPT), but some patients test negative for all three. This report describes a man with behavioral-variant FTD whose standard genetic tests were negative; broader sequencing then found a variant in NEK1, a gene better known in ALS. Whether NEK1 truly causes isolated FTD is still uncertain, but cases like this gradually expand the list of genes that may contribute to inherited frontotemporal dementia.

A repeat expansion in the C9orf72 gene is the most common genetic cause of frontotemporal dementia, but it is unclear what "intermediate-length" expansions, shorter than the classic disease-causing ones, actually do. Studying skin cells from carriers, researchers found long expansions produced the expected disease-related changes, while intermediate expansions altered energy metabolism without obvious cellular damage. The work helps clarify which C9orf72 expansion sizes are harmful, important for interpreting genetic test results and counseling families.

TMEM106B is a gene that influences a person's risk of frontotemporal lobar degeneration. Drawing on two large frontotemporal dementia cohorts (UCSF and the ALLFTD study), researchers measured the TMEM106B protein in spinal fluid and looked for links to patients' clinical features in both inherited and non-inherited disease. Connecting this genetic risk factor to a measurable protein and to symptoms could help with diagnosis, predicting the course of illness, and identifying who might benefit from future TMEM106B-directed treatments.

Mutations in the MAPT gene, which makes the tau protein, can directly cause inherited frontotemporal dementia (FTLD-tau). To study this, researchers built an improved, lower-cost mouse model carrying the human disease-causing P301L MAPT mutation that reliably develops tau pathology and memory problems. Cleaner, more accessible animal models like this make it easier for laboratories worldwide to investigate how MAPT mutations damage the brain and to test potential tau-targeting treatments.

The C9orf72 repeat expansion is the most common genetic cause of frontotemporal dementia and ALS. This review explains how the expansion harms brain cells in two ways, toxic "dipeptide repeat" proteins it produces, and loss of the gene's normal function in microglia (the brain's immune cells), which impairs their clean-up and immune roles. It also surveys how these mechanisms could become biomarkers or treatment targets, framing where C9orf72-directed therapy research is headed.

A repeat expansion in the C9orf72 gene is the most common inherited cause of frontotemporal dementia and ALS, and good animal models are needed to test therapies. Researchers delivered the disease-causing genetic repeats into mice and tracked the results, reproducing hallmark ALS/FTD features and teasing apart the two ways the mutation may cause harm, too much of a toxic product versus too little of the normal gene. Models like this give scientists a clearer testing ground for future C9orf72-targeted treatments.

GENFI (the Genetic Frontotemporal Dementia Initiative) is a major international study following families that carry a known FTD-causing change in the GRN, MAPT, or C9orf72 gene, both people already affected and at-risk relatives who carry the mutation but have no symptoms yet. By tracking biomarkers and clinical changes over years, it aims to detect the disease at its earliest stage and build the tools needed to test preventive, gene-targeted treatments. This is the Lille, France cohort.

PBFT02 is an investigational gene therapy designed to deliver a working copy of the GRN gene to the brain, raising levels of the progranulin protein. This study assesses its safety, tolerability and effect in people with frontotemporal dementia who carry mutations in the GRN or C9orf72 genes. Participants must be confirmed mutation carriers with a clinical FTD diagnosis; sites include the US, Australia and Brazil. The study is currently active but not enrolling new participants. Questions about genetic FTD trials are best discussed with your specialist team.

This study explores how the genetic makeup (genotype) of frontotemporal dementia and related disorders, including ALS, primary lateral sclerosis, and hereditary spastic paraplegia, connects to the observable signs and symptoms (phenotype), and works to develop biomarkers that could aid treatment development. Linking specific genes to how the illness behaves helps refine diagnosis and supports the design of gene-targeted therapy trials across this overlapping family of conditions.

This trial tests AVB-101, a one-time gene therapy for frontotemporal dementia caused by mutations in the GRN (progranulin) gene. In FTD-GRN, low levels of the progranulin protein lead to nerve-cell loss; AVB-101 aims to restore progranulin toward normal levels and potentially slow or stop the disease. It is an early-stage safety-and-effect study, with no placebo, for people aged 30 to 75 who carry a GRN mutation and have early FTD symptoms, at sites in the US, Belgium, Canada and Italy. Discuss eligibility with your care team.

ALLFTD is a large North American research consortium studying the full range of frontotemporal lobar degeneration, including families carrying mutations in the C9orf72, GRN, MAPT or TBK1 genes. Participants, both mutation carriers and at-risk relatives, undergo cognitive testing, brain imaging and biomarker collection over time to map how genetic FTD begins and progresses and to prepare for future treatment trials. It is observational. Members of families with a known FTD gene, or a strong inherited FTD history, may be eligible; ask your care team about joining.

This international study looks at young people, aged 9 to 17, who have a parent or close relative carrying a frontotemporal dementia gene mutation (in MAPT, GRN or C9orf72). By following brain development and thinking skills through childhood and adolescence, decades before any symptoms could appear, researchers hope to understand the earliest effects of these genes on the developing brain. It is observational, involving no treatment. Families already connected to genetic-FTD research can ask the study team whether their children are eligible.